Clinical Management of Canine Transmissible Venereal Tumor: Why Vincristine Still Leads

Canine Transmissible Venereal Tumor (CTVT) is one of the most frequently encountered tumors in dogs, particularly in countries like India where it contributes to nearly 23–43% of all canine cancers¹. The disease is unique because it is transmitted through direct contact, most commonly during coitus, although non-sexual routes such as licking or biting also play a role. This transmissible nature, combined with uncontrolled breeding and a large stray population, makes CTVT a persistent clinical concern. 

Clinical Presentation and Diagnostic Clues 

In practice, CTVT presents with characteristic lesions that are often sufficient to raise suspicion during physical examination. The tumors appear as friable, cauliflower-like masses with a reddish hue due to their rich vascularity. They are prone to bleeding even with minimal manipulation, and affected animals typically present with a foul-smelling, serosanguinous discharge. In male dogs, the tumor is commonly located at the base of the penis or prepuce, while in females, it often obscures the vulvar region. These findings are consistent with earlier observations¹. 

Limitations of Conventional Therapies 

Although multiple treatment modalities such as surgery, radiation, and chemotherapy have been explored, each has its limitations. Surgical excision may be effective for small localized tumors but carries a high recurrence rate, especially in larger masses where recurrence can reach up to 50–68%. Chemotherapeutic agents such as vincristine, doxorubicin, and cisplatin are widely used, but systemic toxicity and drug resistance remain important challenges¹. 

Emerging Role of Scaffold-Based Chemotherapy 

Recent advancements have introduced the concept of drug-loaded scaffolds, which aim to improve drug delivery and reduce systemic toxicity. These scaffolds allow controlled release of chemotherapeutic agents, enhancing bioavailability while minimizing adverse effects. This approach is particularly valuable in veterinary oncology, where treatment compliance and safety are critical considerations¹. 

Comparative Efficacy: Vincristine vs Cisplatin Scaffolds 

The study findings clearly demonstrate a superior response with vincristine scaffold therapy. Dogs treated with vincristine scaffolds showed rapid tumor regression, with nearly 50% reduction in tumor size within the first week and complete regression by the second week. Importantly, no recurrence or significant adverse effects were observed during the treatment period and subsequent three-month follow-up¹. 

In contrast, cisplatin scaffold therapy resulted in only moderate tumor regression. Although some reduction in size was noted, the response was slower and less complete. These findings highlight the continued relevance of vincristine as the primary chemotherapeutic agent for CTVT. 

The mechanism of action of vincristine involves disruption of microtubule formation, leading to arrest of the cell cycle at metaphase and induction of apoptosis through caspase pathways^1,2,3. 

Histopathological Correlation with Clinical Response 

Histopathological evaluation further supports the clinical findings. Tumors treated with vincristine scaffolds showed extensive necrosis, reduced mitotic activity, and increased apoptosis. The presence of shrunken cells with condensed chromatin and fragmented nuclei indicates active tumor regression. Over time, these areas were replaced by collagen-rich connective tissue, suggesting healing and tissue remodeling. 

Cisplatin-treated tumors also showed degenerative changes but to a lesser extent. The persistence of viable tumor cells in many areas explains the incomplete clinical response observed in this group^1,4. 

Clinical Takeaways for Practitioners 

From a practical standpoint, vincristine scaffold therapy offers a reliable, effective, and safe treatment option for CTVT. Early diagnosis and timely initiation of therapy are crucial for achieving optimal outcomes. Regular monitoring during treatment is essential, particularly to assess hematological parameters and detect any early signs of toxicity. 

Conclusion 

CTVT remains a significant oncological challenge in canine practice, but advances in drug delivery systems are improving treatment outcomes. The evidence strongly supports the use of vincristine scaffolds as a first-line therapy due to their rapid efficacy, minimal recurrence, and favorable safety profile. As veterinary oncology continues to evolve, such targeted approaches are likely to redefine standard treatment protocols. 

Reference: 

1. Kumar A, Jadon NS, Zaidi MG, Kandpal M, Saini R. Transmissible Venereal Granuloma Invasiveness and Response to Chemotherapeutics in Canine. Int. J. Contemp. Res. Multi.[Internet]. 2024;3(3):140-7. https://multiarticlesjournal.com/counter/d/3-3-58/IJCRM-2024-3-3-58.pdf 

2. Ganguly B, Das U, Das AK. Canine transmissible venereal tumour: a review. Vet Comp Oncol. 2016;14:1-12. https://drive.google.com/file/d/1JAA2BdHoRo4bZ_V7wDn_quknNNNu_9pn/view 

3. Antonov A. Successful treatment of canine transmissible venereal tumor using vincristine sulfate. Adv Res. 2017;5(5):1-5. Article no.AIR.20017. ISSN: 2348-0394. https://www.researchgate.net/profile/Anton-Antonov-4/publication/282421949_Successful_Treatment_of_Canine_Transmissible_Venereal_Tumor_Using_Vincristine_Sulfate/links/5671620708ae0d8b0cc2f1c1/Successful-Treatment-of-Canine-Transmissible-Venereal-Tumor-Using-Vincristine-Sulfate.pdf 

4. Hiblu MA, Khabuli NM, Gaja AO. Canine transmissible venereal tumor: First report of three clinical cases from Tripoli, Libya. Open veterinary journal. 2019 Apr 1;9(2):103. https://pmc.ncbi.nlm.nih.gov/articles/PMC6626151/pdf/OpenVetJ-9-103.pdf